Trials / Completed
CompletedNCT00097539
National Cooperative Growth Study (NCGS): A Post-marketing Surveillance Program for Nutropin, Nutropin AQ, Nutropin Depot, and Protropin
Genentech National Cooperative Growth Study (NCGS) Post-Marketing Surveillance Program For Nutropin AQ® (Somatropin [rDNA Origin] Injection), Nutropin® (Somatropin [rDNA Origin] for Injection), and Protropin® (Somatrem for Injection)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 65,205 (actual)
- Sponsor
- Genentech, Inc. · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The purpose of this multicenter, open-label, observational, post-marketing surveillance study is to collect long term safety and efficacy information on growth hormone (GH) products: Protropin (somatrem for injection), Nutropin (somatropin for injection), Nutropin AQ (somatropin for injection), and Nutropin Depot (somatropin for injectable suspension) in the treatment of pediatric growth disorders for which GH is prescribed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Somatrem | |
| BIOLOGICAL | Somatropin |
Timeline
- Start date
- 1985-10-01
- Primary completion
- 2010-06-01
- Completion
- 2010-06-01
- First posted
- 2004-11-25
- Last updated
- 2017-02-15
- Results posted
- 2017-02-15
Source: ClinicalTrials.gov record NCT00097539. Inclusion in this directory is not an endorsement.